Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | OGA | O60502 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601426 | 0.92 | RAB9A (0.57) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL18555777 | 0.88 | RAB9A (0.64) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL3895677 | 0.85 | RAB9A (0.72) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL25141661 | 0.85 | NPC1 (0.62) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL13059656 | 0.84 | RAB9A (0.60) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL12734207 | 0.84 | HRH3 (0.57) | RAB9ANPC1KMT2AHRH3MAPT | |
| SCHEMBL7326778 | 0.84 | RAB9A (0.71) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL31239342 | 0.84 | RAB9A (0.60) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL23768897 | 0.84 | RAB9A (0.60) | RAB9ANPC1KMT2AHRH3CRBN | |
| SCHEMBL5759243 | 0.83 | HRH3 (0.59) | RAB9ANPC1KMT2AHRH3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | RAB9A 1687/4885NPC1 14/4885KMT2A 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.